ClinicalTrials.gg
CompletedNCT07222059Updated Feb 3, 2026

Phase 3 Single Arm, Open Study on vYF in Adults

A Phase 3 interventional study of Yellow fever vaccine (live) in Yellow Fever, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 4 sites in Japan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
254
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing Yellow Fever Vaccine in Yellow Fever — 3 open to participants now, 7 under way, 1 of them phase 3. Yellow Fever Vaccine · Yellow Fever.

Enrollment
9th of 18
254 · median 181
Started
2025
with 2 others
Phase 3
6 of 18
1 open now
Registered
18th of 18
by date
Lead sponsor
4 of 18
Sanofi Pasteur, a Sanofi Company

Among the 18 studies testing Yellow Fever Vaccine in Yellow Fever, this one is the 9th largest by enrollment, is one of 3 that started in 2025, is one of 6 in phase 3, and was the 18th registered.

Yellow Fever

52 studies on the registry are indexed under Yellow Fever; 10 are open to participants now.

Browse Yellow Fever studies →

Open to participants now

3 of the 18 studies testing Yellow Fever Vaccine in Yellow Fever are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Yellow Fever Vaccine

Yellow Fever Vaccine: first FDA approval 1999 (Yf-Vax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Yellow Fever studies recruiting now, 1 sets no upper age limit and 6 stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Yellow Fever Vaccine in Yellow Fever, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and immunogenicity of vYF in adults aged 18 years and over in Japan.

Study details include:

  • The study duration will be up to approximately 1 month.
  • One single dose of vYF will be administrated subcutaneously at the 1st visit.
  • The visit frequency will be Day 01 (Visit 01) and Day 29 (Visit 02). One telephone call (TC) will be planned at Day 15.

Number of Participants:

A total of 254 participants is expected to be included in the study with the aim to obtain a total of 203 evaluable participants.

Study Arms and Duration:

Eligible participants will receive, subcutaneously, a single dose of vYF vaccine on Day 1.

The duration of each participation will be approximately 1 month for each participant.

Read the detailed description

Duration of study participation: approximately 1 month for each participant

03

Conditions studied

  • Yellow Fever

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Aged from 18 years on the day of inclusion*

    * "From 18 years" means from the day of the 18th birthday

  • Participants who are healthy as determined by medical evaluation including medical history and physical examination.
  • Able to attend all scheduled visits and to comply with all study procedures
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

    • Is of non-. To be considered of non-childbearing potential, a female must be for at least 1 year, or surgically sterile.

OR

. Is of childbearing potential and agrees to use an effective method or abstinence from at least 4 weeks prior to study intervention administration until at least 4 weeks after study intervention administration.

A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) before any dose of study intervention on Day 01 and will be repeated on Day 29 to confirm the participant is still not pregnant within the 28 days of vaccine administration.

- form (ICF) has been signed and dated Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy, or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • Known history or laboratory evidence of infection.
  • Known history of or seropositivity
  • Known history of FV infection, Japanese encephalitis (JE) excluded
  • Known systemic to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances
  • Personal or family history of thymic pathology (thymoma, thymectomy, or myasthenia).
  • Chronic illness* that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion, including , such as leukemia, or lymphoma

    * Chronic illness may include, but is not limited to cardiac disorders, renal disorders, auto-immune disorders, diabetes, psychiatric disorders or chronic infection

  • Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 37.5°C [or ≥ 99.5°F]). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion.
  • Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine in the 4 weeks following the study vaccination (prior to Visit 2 on Day 29), except for influenza vaccination, which may be received at least 2 weeks before study vaccines. This exception includes pandemic influenza vaccines including monovalent pandemic influenza vaccines.
  • Previous vaccination against YF.
  • Receipt of immune globulins, blood, or blood-derived products in the past 6 months.
  • Administration of any anti-viral within 2 months preceding the vaccination and up to the 6 weeks following the vaccination.
  • Participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the course of the study in another clinical study investigating a vaccine, drug, medical device, or medical procedure.
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
  • Planned travel in a YF endemic country within 28 days of vaccine administration.
  • For participants greater than 60 years at the time of enrolment: any underlying medical condition (eg, cardiovascular disorders, organ failure) which could increase risk of a serious viscerotropic event or serious neurologic events.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
254 participants (actual)

Study arms

  • Experimental
    vYF

    One single dose of vYF will be administered subcutaneously at the 1st visit

    Biological: Yellow fever vaccine (live)

Interventions

  • Pharmaceutical form:Powder and diluent for suspension for injection-Route of administration:Subcutaneous

    Also known as: vYF vaccine

06

What researchers measure

Primary outcomes

  1. Percentage of participants with seroconversion to YF virus in YF-naive participants

    Seroconversion rates will be assessed using a YF MN assay Seroconversion is defined as a 4-fold increase in neutralizing Ab (NAb) titers as compared to the pre-vaccination value (Day 01)

    Time frame: 28 days after one dose of vYF vaccine

Secondary outcomes

  1. Percentage of participants with seroprotection to YF virus

    Seroprotection is defined as NAb titers ≥ 10 (1/dil) at the corresponding timepoint

    Time frame: At Day 01 and Day 29

  2. Percentage of participants with seroconversion to YF virus

    Seroconversion rates will be assessed using a YF MN assay Seroconversion is defined as a 4-fold increase in neutralizing Ab (NAb) titers as compared to the pre-vaccination value (Day 01)

    Time frame: 28 days after one dose of vYF vaccine

  3. Geometric Mean Titers (GMTs) of neutralizing antibodies against YF virus

    Antibody titers are expressed as GMTs

    Time frame: At Day 01 and Day 29

  4. Geometric Mean Titers Ratio (GMTRs) of neutralizing antibodies against YF virus

    GMTRs Day 29/Day 01

    Time frame: At Day 01 and Day 29

  5. Number of participants with immediate adverse events

    Immediate adverse events are any unsolicited systemic adverse events reported in the 30 minutes after vaccination

    Time frame: Within 30 minutes after vaccination

  6. Number of participants with solicited injection site reactions

    Solicited injection site reactions: injection site pain, injection site erythema, injection site swelling

    Time frame: Within 7 days after vaccination

  7. Number of participants with solicited systemic reactions

    Solicited systemic reactions: fever, headache, fatigue, myalgia

    Time frame: Within 14 days after vaccination

  8. Number of participants with unsolicited adverse events (AEs), including adverse events of special interest (AESIs)

    Unsolicited (spontaneously reported) AEs, not fulfilling criteria for solicited adverse reactions, including AESIs

    Time frame: Within 28 days after vaccination

  9. Number of participants with serious adverse events (SAEs) including serious AESIs

    SAEs including serious AESIs

    Time frame: Within 28 days after vaccination

  10. Number of participants with related SAEs and all deaths

    Related SAEs and all deaths

    Time frame: From Day 01 to Day 29 after vaccination

07

Study locations

4 sites
  • Investigational Site Number : 3920001
    Takatsuki, Osaka 569-1192, Japan
  • Investigational Site Number : 3920002
    Chūō, Tokyo 103-0025, Japan
  • Investigational Site Number : 3920003
    Shinjuku-ku, Tokyo 169-0072, Japan
  • Investigational Site Number : 3920004
    Taitō City, Tokyo 111-0036, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Dec 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2025
First posted
Oct 29, 2025
StartActual
Oct 23, 2025
Primary completionActual
Dec 25, 2025
CompletionActual
Dec 25, 2025
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07222059
Responsible party
Sponsor
First posted
Oct 29, 2025
Start date
Oct 23, 2025
Primary completion
Dec 25, 2025
Completion
Dec 25, 2025
Last update
Feb 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yellow Fever Vaccine

Start the discussion